The FDA has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC) being developed by Seattle Genetics and Astellas. Currently in phase 2, enfortumab vedotin is being investigated for patients with locally...
Original Article: Seattle Genetics and Astellas gain Breakthrough Designation for urothelial cancer treatment